Elite Pharmaceuticals Inc - ELTP STOCK NEWS

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) announced the appointment of Robert Chen, CPA/MPA, as its new Chief Financial Officer (CFO), effective May 16, 2022, succeeding Marc Bregman. Chen, with over 20 years of experience in financial leadership within the life sciences sector, previously held significant roles at notable firms including KBP Biosciences and Novartis. His expertise in financial reporting and operational management is expected to strengthen Elite's executive team and contribute positively to its financial operations.

Elite Pharmaceuticals (OTCQB:ELTP) announced FDA approval for doxycycline hyclate 100 mg tablets, an antibiotic targeting various bacterial infections. This approval was achieved in collaboration with Praxgen Pharmaceuticals. The company specializes in niche generic products and operates a registered facility in Northvale, NJ. The approval could enhance Elite's market presence and revenue potential in the competitive pharmaceutical space.

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported a strong performance for the third quarter of fiscal year 2022, ended December 31, 2021. Consolidated revenues reached $9.0 million, up 48% year-over-year, driven by increased sales of Amphetamine IR Tablets and ER Capsules. The company also posted an operating profit of $1.8 million, an increase of $0.8 million compared to the prior year, and net income of $2.3 million. A conference call is scheduled for February 15 at 11:30 AM EST to discuss these results and recent developments.

Elite Pharmaceuticals (OTC PINK:ELTP) will announce its third quarter financial results for the fiscal year 2022 on February 14, 2022. Following the release, management will conduct a live conference call on February 15, 2022, at 11:30 AM EST to review financials and operational updates. Shareholders are encouraged to submit questions prior to the call. Elite Pharmaceuticals specializes in developing niche generic products and operates a cGMP facility in Northvale, NJ.

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported second quarter fiscal year 2022 financial results for the period ending September 30, 2021. The company achieved revenues of $8.6 million, reflecting a 16% increase from the previous year, driven by strong sales of Amphetamine IR Tablets and ER Capsules. Operating profits rose to $1.4 million, and net income was $1.8 million. A conference call regarding these results is scheduled for November 16, 2021, at 11:30 AM EST.

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) will release its second quarter financial results for the fiscal year 2022 on November 15, 2021. A live conference call is scheduled for November 16 at 11:30 AM EST, where management will discuss financial and operating results, alongside a business update. Stakeholders are encouraged to submit questions before the call. Elite Pharmaceuticals focuses on developing niche generic products and operates a cGMP facility in Northvale, NJ. For more details, visit www.elitepharma.com.

Elite Pharmaceuticals (OTCQB:ELTP) reported a 6% decline in total revenues for Q1 FY 2022, reaching $7.1 million compared to $7.5 million in the same period last year. This decrease is attributed to the timing of sales of Amphetamine products. However, the company reported stronger margins leading to operating profits of $1.0 million, an increase of $0.2 million year-over-year, and net income of $2.4 million. A conference call is scheduled for August 17, 2021, to discuss the results further.

Elite Pharmaceuticals (OTCQB:ELTP) announced the release of its first quarter financial results for fiscal year 2022 on August 16, 2021. A live conference call to discuss these results and provide a business update is scheduled for August 17, 2021, at 11:30 AM EDT. Stakeholders are encouraged to submit questions ahead of the call. The company specializes in developing niche generic pharmaceutical products and operates a cGMP and DEA registered facility in Northvale, NJ.

Elite Pharmaceuticals reported a significant increase in fiscal year 2021 revenues, totaling $25.4 million, up 41% from the prior year. The revenue growth is primarily driven by sales of generic Adderall and Isradipine products. Operating profits rose to $2.1 million, a substantial improvement of $4.3 million year-over-year, with net income reported at $5.1 million. A conference call is scheduled for June 15, 2021, to discuss these results and future business developments.